HOME >> BIOLOGY >> NEWS
Positive attitude is best prevention against heart disease

"This study has the potential to change how emergency departments triage patients with chest pain." Nisha Chandra-Stobos, M.D.

For years, hospital emergency physicians have used nitrogylcerin as a gold standard for identifying heart disease as a cause of chest pain. If a patient presents with chest pain, and a nitroglycerin pill or spray under the tongue relieves the pain within a few minutes, the likely diagnosis is coronary artery disease (CAD).

Now a Johns Hopkins study is challenging that belief. Of 459 patients who came to the emergency department at Hopkins' Bayview Medical Center between February and June of this year complaining of chest pain, nitroglycerin relieved chest pain in about 39 percent of patients, whether or not they turned out to have heart disease. Overall, nitroglycerin was only 28 percent accurate in predicting CAD as the source of pain. These findings will be presented Nov. 12 at the American Heart Association's annual Scientific Sessions in Anaheim, Calif.

"This study has the potential to change how emergency departments triage patients with chest pain," says Nisha Chandra-Stobos, M.D., senior author of the study and director of the coronary intensive care unit at Bayview. "Our data suggest that despite the commonly held belief, pain relief with nitroglycerin does not predict coronary artery disease and should not be used to guide diagnosis."

Nitroglycerin works by relaxing the veins (reducing the amount of blood that returns to the heart and easing the heart's workload) and arteries (increasing the heart's blood supply). It's the drug most often used for the one in five patients who comes to the ED complaining of chest pain.

The patients studied had an average age of 58. Forty-six percent were male; 44 percent were smokers; 25 percent were diabetic and 38 percent had a known history of CAD. After initial treatment with nitroglycerin, 261 (57 percent) underwent further cardiac test
'"/>

Contact: Karen Blum
kblum@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
13-Nov-2001


Page: 1 2

Related biology news :

1. Positive attitude is best prevention against heart disease
2. Nationwide Study Finds HIV-Positive Women Are At High Risk For Cervical Human Papillomavirus Infection
3. Native Gray Ants Play Positive Role In Valley Peach Orchards
4. Drug Therapy Shows Promise In Preventing Hepatitis Infection In Transplant Recipients Who Receive Hepatitis B Positive Livers, Says One Study
5. HIV-Positive Injection Drug Users Often Dont Receive Protease Inhibitors And May Not Be Aware Of The Drug
6. Long-Term Study Looks At HIV Positive Men With Few Signs Of Disease Progression, 10-18 Years After Seroconversion
7. Study finds wide attitude gap on wolves
8. Study reveals differing attitudes to PGD among
9. Heritability of attitudes: Twin research in religious perspective
10. Scholar finds parallels between U.S./Japanese attitudes toward wolves
11. Cranfield looks at recycling attitudes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Positive attitude best prevention against heart disease

(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: